Arcadia Biosciences, Inc. (RKDA) Net margin 2017–2025
Arcadia Biosciences, Inc. (RKDA) net profit margin by fiscal year — reported net income divided by reported revenue.
-48.1%FY2025 · since FY2017: -390.1% → -48.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -48.1% | +91.4 pp |
| FY2024 | -139.5% | +174.4 pp |
| FY2023 | -313.9% | -106.6 pp |
| FY2022 | -207.3% | +8.9 pp |
| FY2021 | -216.2% | -158.3 pp |
| FY2020 | -57.9% | +2406.1 pp |
| FY2019 | -2464.1% | -1543.3 pp |
| FY2018 | -920.8% | -530.6 pp |
| FY2017 | -390.1% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More RKDA financial trends
RKDA RevenueRKDA Net incomeRKDA Gross profitRKDA Gross marginRKDA Operating incomeRKDA Operating marginRKDA Operating cash flowRKDA Free cash flowRKDA Capital expendituresRKDA Return on equityRKDA Stock buybacksRKDA Dividends paidRKDA Total assetsRKDA Total liabilitiesRKDA Shareholders’ equityRKDA overview →